Q-omics provides the consensus-scored IL36RN profile across patient tissues and cancer cell-line models. IL36RN expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, IL36RN is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, IL36RN RNA expression shows 12,996 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight BLCA, THCA, and HNSC as cancer lineages where IL36RN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL36RN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL36RN survival associations across molecular data types. IL36RN RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL36RN RNA expression–survival associations across cancer types. High IL36RN expression shows unfavorable associations in BLCA, KICH, LIHC, UVM, UCEC and KIRP. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for IL36RN RNA expression.
This table summarizes IL36RN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IL36RN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL36RN shows higher tumor expression in THCA, LUSC, LUAD, COAD, BLCA and BRCA. The THCA box plot shows higher IL36RN RNA expression in tumor versus normal tissue (log2 FC = +1.645, t-test p < 0.001).
This table shows molecular features associated with IL36RN in patient tissues and cancer cell lines. In patient samples, IL36RN shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL36RN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_NSCLC_LUAD.
